MacroGenics Inc. (NASDAQ:MGNX) traded down 1.5% during mid-day trading on Friday . The company traded as low as $29.46 and last traded at $29.61, with a volume of 67,210 shares. The stock had previously closed at $30.05.

A number of equities research analysts have recently issued reports on the company. Citigroup Inc. cut MacroGenics from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $27.00 to $32.00 in a research note on Thursday, August 4th. TheStreet upgraded MacroGenics from a “sell” rating to a “hold” rating in a research note on Friday, August 5th. Zacks Investment Research upgraded MacroGenics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 20th. Morgan Stanley reiterated a “hold” rating on shares of MacroGenics in a research note on Thursday, June 30th. Finally, Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of MacroGenics in a research note on Tuesday, June 14th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $38.71.

The company’s 50-day moving average price is $30.17 and its 200 day moving average price is $23.47. The stock’s market cap is $1.03 billion.

MacroGenics (NASDAQ:MGNX) last announced its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported $1.12 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.02) by $1.14. During the same period last year, the business posted ($0.71) EPS. The firm earned $80.67 million during the quarter, compared to analyst estimates of $27.22 million. The company’s revenue was up 1100.4% on a year-over-year basis. On average, equities research analysts predict that MacroGenics Inc. will post ($1.29) earnings per share for the current year.

In other MacroGenics news, CMO Jon Marc Wigginton sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $27.22, for a total value of $136,100.00. Following the completion of the sale, the chief marketing officer now owns 5,000 shares of the company’s stock, valued at $136,100. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Lynn Cilinski sold 8,922 shares of the firm’s stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $27.22, for a total value of $242,856.84. Following the completion of the sale, the vice president now directly owns 10,845 shares of the company’s stock, valued at approximately $295,200.90. The disclosure for this sale can be found here.

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.